Cargando…

Reply to Decroo et al.: High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis

Detalles Bibliográficos
Autores principales:	Dooley, Kelly E., Miyahara, Sachiko, von Groote-Bidlingmaier, Florian, Sun, Xin, Hafner, Richard, Rosenkranz, Susan L., Ignatius, Elisa H., Nuermberger, Eric L., Moran, Laura, Donahue, Kathleen, Swindells, Susan, Vanker, Naadira, Diacon, Andreas H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301745/ https://www.ncbi.nlm.nih.gov/pubmed/32130866 http://dx.doi.org/10.1164/rccm.202002-0359LE

Ejemplares similares

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
por: Abulfathi, Ahmed A., et al.
Publicado: (2021)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Laboratory test result interpretation for primary care doctors in South Africa
por: Vanker, Naadira, et al.
Publicado: (2017)

Optimizing β-Lactams against Tuberculosis
por: de Jager, Veronique R., et al.
Publicado: (2020)

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial
por: Bouton, Tara C., et al.
Publicado: (2017)

The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance
por: Van Deun, Armand, et al.
Publicado: (2020)

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses
por: Svensson, Robin J., et al.
Publicado: (2017)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis
por: Decroo, Tom, et al.
Publicado: (2020)

Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes
por: Decroo, Tom, et al.
Publicado: (2020)

High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance
por: Martinecz, Antal, et al.
Publicado: (2023)

Effect of rifampicin combination-regimens against multi-drug resistant strains in North India
por: Rafeeq, Misbahuddin M, et al.
Publicado: (2022)

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
por: Stemkens, Ralf, et al.
Publicado: (2023)

Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2019)

The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide
por: Lin, Huang-Shen, et al.
Publicado: (2016)

Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
por: Ciza, François, et al.
Publicado: (2020)

Moxifloxacin concentration correlate with QTc interval in rifampicin-resistant tuberculosis patients on shorter treatment regimens
por: Kusmiati, Tutik, et al.
Publicado: (2022)

Mycobacterium shinjukuense infection successfully treated with clarithromycin, rifampicin, and ethambutol
por: Nakamura, Kayo, et al.
Publicado: (2023)

New drugs to treat tuberculosis
por: Swindells, Susan
Publicado: (2012)

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model
por: Kendall, Emily A., et al.
Publicado: (2017)

Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin
por: Mankhatitham, W, et al.
Publicado: (2010)

Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
por: Zhang, Zehua, et al.
Publicado: (2014)

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
por: Svensson, Elin M., et al.
Publicado: (2015)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022)

In Vitro Assessment of the Interaction Potential of Ocimum basilicum (L.) Extracts on CYP2B6, 3A4, and Rifampicin Metabolism
por: Kumar, Saneesh, et al.
Publicado: (2020)

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
por: Svensson, Elin M, et al.
Publicado: (2018)

Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
por: Cai, Xingshan, et al.
Publicado: (2022)

Current strategies to treat tuberculosis
por: Podany, Anthony T., et al.
Publicado: (2016)

Decontamination regimens: do not forget half of the protocol. Author's reply
por: Briegel, Josef, et al.
Publicado: (2022)

Comparison of the ‘Denver regimen’ against acute tuberculosis in the mouse and guinea pig
por: Ahmad, Zahoor, et al.
Publicado: (2010)

Thrombocytopenia due to rifampicin
por: Dixit, Ramakant, et al.
Publicado: (2012)

Rifampicin-induced thrombocytopenia
por: Verma, Ajay Kumar, et al.
Publicado: (2010)

Thrombocytopenia due to rifampicin
por: Gupta, Prahlad Rai
Publicado: (2012)

Rifampicin for COVID-19
por: Panayiotakopoulos, George D, et al.
Publicado: (2022)

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens
por: Swindells, Susan, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_lqljlmbl3u27gf0g9giaqckstb